OBJECTIVE: The objective of this research was to identify the rate of unexpected malignancies after laparoscopic-assisted supracervical hysterectomies (LASH) and describe the therapy regime. METHODS: The research is based on a retrospective chart analysis of patients undergoing a simple hysterectomy in the gynecological endoscopy department of a general hospital in Germany. RESULTS: 2,577 simple hysterectomies conducted between March 2005 and March 2010 were sub-classified in different types of hysterectomies (vaginal-, abdominal-, total-, abdominal supracervical hysterectomy, LAVH, and LASH). This study focuses on the LASH sub-group of 1,584 patients and does not make any comparisons to other operative approaches. Out of the 1,584 patients, 87.8 % (n = 1,391) received preoperative screening to exclude dysplasia or malignancy based on the policy of the German Association for gynecology and obstetrics (DGGG). The screening includes cytology (Pap-smear) and preoperative ultrasound of the uterus or dilatation and curettage (d&c). Unexpected malignancies were found in 0.25 % (n = 4) of the patients pre-screened according to DGGG protocol. Out of the four malign patients, two had endometrial cancer. Two patients had leiomyosarcoma. CONCLUSION: The study shows that there is a small probability of unexpected malignancies even in correctly pre-screened patients for LASH procedures. Yet in the short-term (28-52 months), malign patients remain recurrence free after treatment. LASH is therefore a good procedure for assumed benign disease.
OBJECTIVE: The objective of this research was to identify the rate of unexpected malignancies after laparoscopic-assisted supracervical hysterectomies (LASH) and describe the therapy regime. METHODS: The research is based on a retrospective chart analysis of patients undergoing a simple hysterectomy in the gynecological endoscopy department of a general hospital in Germany. RESULTS: 2,577 simple hysterectomies conducted between March 2005 and March 2010 were sub-classified in different types of hysterectomies (vaginal-, abdominal-, total-, abdominal supracervical hysterectomy, LAVH, and LASH). This study focuses on the LASH sub-group of 1,584 patients and does not make any comparisons to other operative approaches. Out of the 1,584 patients, 87.8 % (n = 1,391) received preoperative screening to exclude dysplasia or malignancy based on the policy of the German Association for gynecology and obstetrics (DGGG). The screening includes cytology (Pap-smear) and preoperative ultrasound of the uterus or dilatation and curettage (d&c). Unexpected malignancies were found in 0.25 % (n = 4) of the patients pre-screened according to DGGG protocol. Out of the four malignpatients, two had endometrial cancer. Two patients had leiomyosarcoma. CONCLUSION: The study shows that there is a small probability of unexpected malignancies even in correctly pre-screened patients for LASH procedures. Yet in the short-term (28-52 months), malignpatients remain recurrence free after treatment. LASH is therefore a good procedure for assumed benign disease.
Authors: Sarah E Rutstein; Matthew T Siedhoff; Elizabeth J Geller; Kemi M Doll; Jennifer M Wu; Daniel L Clarke-Pearson; Stephanie B Wheeler Journal: J Minim Invasive Gynecol Date: 2015-10-22 Impact factor: 4.137
Authors: Ann Peters; Amanda M Sadecky; Daniel G Winger; Richard S Guido; Ted T M Lee; Suketu M Mansuria; Nicole M Donnellan Journal: Int J Gynecol Cancer Date: 2017-07 Impact factor: 3.437
Authors: Matthew T Siedhoff; Stephanie B Wheeler; Sarah E Rutstein; Elizabeth J Geller; Kemi M Doll; Jennifer M Wu; Daniel L Clarke-Pearson Journal: Am J Obstet Gynecol Date: 2015-03-24 Impact factor: 8.661
Authors: Ana M Rodriguez; Mehmet R Asoglu; Muhammet Erdal Sak; Alai Tan; Mostafa A Borahay; Gokhan S Kilic Journal: Eur J Obstet Gynecol Reprod Biol Date: 2015-11-28 Impact factor: 2.831
Authors: Elizabeth A Pritts; David J Vanness; Jonathan S Berek; William Parker; Ronald Feinberg; Jacqueline Feinberg; David L Olive Journal: Gynecol Surg Date: 2015-05-19